INFLUENCE OF IMIDAZOLE CARBAMOXIDE ON PLATELET FUNCTION. P. Kubisz, P. Klimper and S. Czornobaj, Division of Hematology, University Hospital, Oran, Algeria, Hemosbasis Laboratory, Departmental Hospital, Ceska, Czechoslovakia, Division of Hematology, Charles University Hospital, Prague, Czechoslovakia and Department of Infectious Diseases, General Hospital, Malmo, Sweden.

Imidazol carbamoxide (DTIC, NC-43088) is a cytostatic drug used in the treatment of malignant melanoma under the trade name of Lascarazine®. Its influence on platelet function, blood coagulation and fibrinolysis was investigated in vitro. At a concentration of 160 μg/ml it inhibited the increase in light transmission induced in platelet-rich plasma by standardized freezing and thawing. It also retarded the retraction of resealable clot. This therefore indicated a stabilizing effect on the platelets at this dosage.

At a concentration of 40 μg/ml the drug did not significantly influence the platelet function in vitro. This concentration corresponds to therapeutic plasma levels. At current dosage of the drug any bleeding tendency due to platelet dysfunction therefore seems unlikely.

INFLUENCE OF LOW DOSE HEPARIN AND OF ACETYLSALICYLIC ACID ON ALTERATIONS OF THE HEMOSTATIC MECHANISM BY VENOUS OCCLUSION. H. Vilarzé and D. Lomé, Blood Coagulation Laboratory, Linz, Austria.

Venous occlusion was used as a model to examine the action of antithrombotic substances. In 15 healthy volunteers, a blood pressure cuff attached to an arm was inflated to 90 mm Hg for 15 minutes. Blood was collected from an antecubital vein prior to and at the end of occlusion. Parameters of coagulation, fibrinolysis, and of platelet function were examined.

At the end of occlusion, factors X and Xa were demonstrable in intact plasma. There was also a diminution of plasminogen and a shortening of the prothrombin time. Cyclic nucleotides were increased. Platelet factor 4 (PF 4) was diminished in platelets, and was demonstrable in plasma after occlusion.

Three groups were formed from these volunteers. Group 1 received 1500 mg acetylsalicylic acid (ASA) per day, group 2 was injected 5000 units heparin s.c. at 12 h intervals, and group 3 received both drugs. After one week of therapy, blood samples were again collected before and after occlusion. In the ASA group, platelet aggregation was diminished. This was not altered by occlusion. PF 4 was neither diminished in platelets nor was it demonstrable in plasma. There was no influence on plasminogen, a factor Xa, and factor Xa were demonstrable in plasma after occlusion. There was no platelet aggregation was diminished. Platelet aggregation was not influenced. In the heparin plus ASA group, factors Xa and Xa were as well as plasma PF 4 were diminished in platelets after occlusion. PF 4 in platelets was not diminished whilst platelet aggregation was inhibited.

These experiments demonstrate a mutual support of ASA and heparin in the prevention of alterations of the heparin mechanism which are likely to provoke an increased thrombotic tendency.

PROSTAGLANDIN-ENDOPEROXIDES AND CYCLIC 3'-5'-AMP IN PLATELETS OF PATIENTS WITH HYPERCOAGULABILITY AND SHOCK. E.M. Hartley, Dept. of Int. Medicine, Justus Liebig University, Gießen, Germany.

To get more insight in platelet function of patients suffering from insufficient flow of the circulation combined with intravascular fibrin formation as a sign of a stimulated coagulation system, the following parameters were determined: 1, the prostaglandin-endoperoxide formation of platelets in response to N-ethylmaleimide and collagen measured as malonaldehyde; 2, the c-AMP content of platelets and plasma according to the Gilman method; 3, the stimulating effect of prostaglandin E1 on the platelets adenylylcyclase activity; 4, the collagen induced platelet aggregation.

Platelet aggregation was reduced. The prostaglandin-endoperoxide formation was unchanged in comparison to normal donors. Plasma c-AMP was increased; whereas the platelet c-AMP content was unaltered, adenylylcyclase activity in response to prostaglandin E1 was reduced. Platelet function recovered concomitantly with the improvement of the circulation and the clotting parameters.